このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

再発・進行性非定型奇形横紋筋肉腫(ATRT)の若年患者に対する新規治療法の研究

2026年11月5日 更新者:Sabine Mueller, MD, PhD

再発性/進行性非定型奇形様横紋筋肉腫(ATRT)を有する小児、青年、若年成人のための新規治療法に関するプラットフォーム研究

This is a multi-treatment arm study that will be conducted through the Pacific Pediatric Neuro-oncology Consortium (PNOC).The study will assess the safety and efficacy of novel therapies and combinatorial strategies for participants with recurrent or progressive ATRT.

調査の概要

詳細な説明

PRIMARY OBJECTIVES:

I. To assess efficacy of each treatment arm based on arm-specific endpoints. II. To evaluate the safety and tolerability of each treatment arm for patients with recurrent/progressive ATRT.

EXPLORATORY OBJECTIVES:

I. To collect additional treatment arm-specific safety and tolerability information as applicable.

II. To determine additional treatment arm-specific time-to-event endpoints. III. To assess the correlations between methylation-based subgroups and objective response and outcome measures.

IV. To collect biologic samples (tumor, blood, CSF) for future biomarker discovery.

V. Additional treatment arm-specific exploratory objectives may be added in each interventional arm.

OUTLINE: Participants will enroll onto a treatment arm as treatment arms open for enrollment. Participants who are taken off treatment on one trial arm for progression or toxicity may enroll on a new treatment arm, if arm-specific eligibility criteria are met. If the study is opened at the treating institution, participants will be followed under the Pediatric Neuro-oncology Consortium (PNOC) COMP protocol until death or withdrawal from study.

研究の種類

介入

入学 (推定)

29

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:PNOC Operations Office
  • 電話番号:415-502-1600
  • メール:PNOC035@ucsf.edu

研究場所

    • California
      • San Francisco、California、アメリカ、94143
        • 募集
        • University of California, San Francisco
        • 主任研究者:
          • Sabine Mueller, MD, PhD, MAS
        • コンタクト:
      • San Francisco、California、アメリカ、94143
        • まだ募集していません
        • University of California, San Francisco
        • 主任研究者:
          • Sabine Mueller, MD, PhD
        • コンタクト:
        • コンタクト:
          • PNOC Operations Office
          • 電話番号:415-502-1600
          • メール:PNOC035@ucsf.edu
    • Maryland
      • Baltimore、Maryland、アメリカ、21218
        • 募集
        • John Hopkins Hospital
        • コンタクト:
          • Kenneth Cohen, MD
          • 電話番号:410-614-5055
          • メール:kcohen@jhmi.edu
        • 主任研究者:
          • Kenneth Cohen, MD
    • Washington
      • Seattle、Washington、アメリカ、98105
        • 募集
        • Seattle Children's Hospital University of Washington, Seattle
        • コンタクト:
        • 主任研究者:
          • Erin Crotty, MD

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

1年~39年 (子、大人)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • In addition to the below, investigators are to refer to arm-specific inclusion criteria in the appendix.

    • Participants must have a pathologic diagnosis of central nervous system (CNS) ATRT, with confirmation of SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily b, member 1 (SMARCB1) (INI1) loss by immunohistochemistry (IHC) and/or biallelic loss of function of SMARCB1 by molecular report. Loss of SWI/SNF Related, Matrix Associated, Actin Dependent Regulator of Chromatin, Subfamily A, Member 4 (SMARCA4) as confirmed by IHC or molecular report is also acceptable but requires study chair approval.
    • Participants must have confirmation of methylation report, co-enrollment on PNOC-030 or sufficient tumor tissue available for methylation-based subgrouping
    • Participants must have recurrent or progressive ATRT.
    • Participants age must be ≥1 and ≤ 39 years at the time of study enrollment. Please refer to arm specific inclusion criteria for potential variations in lower age eligibility limit.
    • Prior Therapy: Participants must have fully recovered from the acute effects of prior anti-cancer therapy, and the following wash-out periods need to be observed prior to enrollment:
  • Systemic myelosuppressive therapy: ≥ 21 days after the last dose (42 days for nitrosoureas or mitomycin C).

  • Intrathecal/intraventricular chemotherapy: > 7 days after the last dose.

  • Small molecule/targeted/biologic agent: ≥ 7 days after the last dose.

  • Monoclonal antibodies: ≥ 21 days after the last dose. Other non-myelosuppressive anti-cancer agents: ≥ 3 drug half-lives after the last dose.

  • CAR-T cell therapy (systemic or intraventricular): > 21 days.

    • Previous radiotherapy. Participants will be eligible following radiotherapy, if they meet the following criteria:

  • Previous craniospinal or total body radiotherapy: Participants must have received their last fraction ≥ 12 weeks prior to enrollment and have evidence of progressive/recurrent evaluable disease post radiation.

  • Previous focal radiotherapy to target lesions: Participants must have received their last fraction to target lesions ≥12 weeks prior to enrollment and have evidence of progressive/recurrent evaluable disease post radiation; investigators are reminded to review potentially eligible cases to avoid confusion with pseudo-progression.

  • Focal radiotherapy to non-target lesions: Participants may have received radiotherapy to nontarget lesions as long as the last fraction was > 14 days prior to enrollment. Participants must have at least one non-irradiated lesion that is evaluable for response.

    • Performance Score: Karnofsky ≥ 50 for participants > 16 years of age and Lansky ≥ 50 for participants ≤ 16 years of age. Participants who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.
    • Corticosteroids: Participants who are receiving corticosteroids must be on a stable or decreasing dose for at least 1 week prior to enrollment. Please also refer to arm-specific inclusion criteria for potential variations in steroid limitations.
    • Organ Function Requirements.

Adequate Bone Marrow Function Defined as:

  • Peripheral absolute neutrophil count (ANC) ≥ 750/mm3
  • Platelet count ≥ 75,000/cubic millimeters (mm3) (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment).

Adequate Renal Function Defined as:

  • Serum creatinine ≤ 1.5 Upper Limit Normal (ULN) based on age and gender

Adequate Liver Function Defined as:

  • Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age; in presence of Gilbert's syndrome, total bilirubin < 3 x ULN or direct bilirubin < 1.5 x ULN
  • Alanine aminotransferase (ALT) ≤ 3 x ULN
  • Aspartate aminotransferase (AST) ≤ 3 x ULN

Adequate Neurologic Function Defined as:

  • Participants with seizure disorder may be enrolled if well controlled. See arm-specific recommendations for potential interactions between anticonvulsant agent(s) with study drug.

    • Effect on the developing human fetus Recommendations on the potential effect of interventional agents on the developing human fetus will be specified in each study arm's details of therapeutic agents. Unless otherwise specified, the effects of study interventions should be considered potentially teratogenic. Thus, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study treatment and four months after its completion. Should a woman become pregnant or suspect she is pregnant while she is participating in this study, or should a male participant's partners become pregnant during study participation, they should inform the treating physician immediately.
    • A legal parent/guardian or patient must be able to understand, and willing to sign, a written informed consent and assent document, as appropriate.
    • Participants must enroll on Pediatric Neuro-oncology Consortium (PNOC) COMP if PNOC COMP is open to accrual at the enrolling institution.

Exclusion Criteria:

  • Evidence of synchronous tumors or other extra-CNS malignancy
  • Participants who are receiving any other investigational agents
  • Participants who are currently receiving other anti-cancer agents
  • Participants with uncontrolled infection or other uncontrolled systemic illness
  • Female participants of childbearing potential who are pregnant or breast-feeding. Female participants of childbearing potential must have a negative serum or urine pregnancy test prior to the start of therapy and throughout study treatment.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition as the intended treatment regimen, as detailed in that arm's treatment description.

Arm A

Inclusion Criteria:

  • Subjects must meet all inclusion criteria for the overall study.
  • Patients must be evaluable per Response Assessment in Pediatric Neuro-Oncology (RAPNO) criteria for medulloblastoma and other leptomeningeal seeding tumors to be evaluated for the primary endpoint (Warren et al. 2018); patients with evaluable but non-measurable disease, including leptomeningeal disease or positive CSF cytology only are eligible.

Patients with recurrent or progressive ATRT who receive surgery only for their disease progression and do not have evaluable disease may be eligible for study treatment but would not be included towards the primary efficacy endpoint (to be discussed with study chairs).

  • Subjects must be able to swallow intact capsules.

  • Adequate Metabolic Function Defined as:

    • Non-fasting glucose ≤ 140 milligrams per deciliter (mg/dL) without the use of antihyperglycemic agents.
    • If non-fasting glucose > 140 mg/dL, a fasting glucose should be done. If fasting glucose ≤ 125 mg/dL without the use of antihyperglycemic agents, participant will meet adequate metabolic function criteria.
    • Triglycerides of < 300 mg/dl and total cholesterol of < 300 mg/dl - can be on lipid lowering medications as needed to achieve.
  • Adequate Cardiac Function Defined as:

    • Electrocardiogram (ECG) must be obtained to verify the Corrected QT Interval (QTC). If an abnormal reading is obtained, the ECG should be repeated in triplicate.
    • QTC < 470 millisecond (msec)

Arm A

Exclusion Criteria:

In addition to not meeting any of the exclusion criteria of the overall study, participation on arm A will also require that subjects do not meet any of the following:

  • Previous exposure to gemcitabine or paxalisib
  • Concomitant use of an antihyperglycemic agent (e.g. metformin)
  • Chronic diarrhea greater than Grade 2

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:非ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Treatment Arm A: Phase I

Participants will receive a combination of gemcitabine and paxalisib with starting dose, 1,200mg/m2 gemcitabine and 15mg/m2 paxalisib (phase I). If this dose level is tolerated, it will be confirmed as the RP2D. However, if the dose limiting toxicity (DLT) is not tolerated, the RP2D will be set at the highest dose level tolerated by the previous group.

Given IV

Cerebral Spinal Fluid (CSF) will be collected for research

Perform blood draw

Undergo imaging procedure

Given orally (PO)

Undergo biopsy

実験的:Treatment Arm A: Efficacy (Phase II)

All participants will receive a combination of gemcitabine and paxalisib over a 28-day cycle, for up to 24 cycles or until they meet criteria to stop treatment, whichever comes first. Gemcitabine will be administered via infusion on days 1, 8, and 15 of each cycle, while paxalisib will be taken daily throughout each cycle.

Given IV

Cerebral Spinal Fluid (CSF) will be collected for research

Perform blood draw

Undergo imaging procedure

Given orally (PO)

Undergo biopsy

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Arm A (Phase I): Proportion of participants who experience dose-limiting toxicity (DLT)
時間枠:up to 28 days

Tolerability is defined as the proportion of participants receiving at least one dose of combination gemcitabine and paxalisib with a reported dose-limiting toxicity (DLT) during cycle 1 for all participants in Phase I.

up to 28 days
Arm A (Phase I): Recommended Phase 2 Dose (RP2D) (Phase I)
時間枠:up to 28 days

The confirmed RP2D of combination gemcitabine and paxalisib implemented for participants enrolled in Phase II will be reported.

up to 28 days
Arm A (Phase II): Rate of Clinical Benefit
時間枠:up to 2 years (24 cycles)

Assess the efficacy of combination gemcitabine and paxalisib for participants in Phase II. Clinical Benefit rate (CBR) is defined as complete response (CR) + partial response (PR) + stable disease (SD), where SD is sustained over 4 months.

up to 2 years (24 cycles)

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Sabine Mueller, MD, PhD、University of California, San Francisco
  • スタディチェア:Ashley Margol, MD, MS、Children's Hospital Los Angeles

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年6月17日

一次修了 (推定)

2035年12月31日

研究の完了 (推定)

2036年12月31日

試験登録日

最初に提出

2026年2月25日

QC基準を満たした最初の提出物

2026年2月25日

最初の投稿 (実際)

2026年3月3日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月9日

QC基準を満たした最後の更新が送信されました

2026年11月5日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する